Table 1 Association of UCHL3 levels with clinical and pathological features of GC patients.

From: UCHL3 depletion inhibits gastric cancer progression and enhances palbociclib sensitivity by regulating the AKT/CCND1 signaling axis via ENO1 ubiquitination

Variables

N

Tumor UCHL3 expression

P value

UCHL3High (%)

UCHL3Low (%)

Age (years)

 <65

91

56 (61.5)

35 (38.5)

0.366

 ≥65

36

19 (52.8)

17 (47.2)

Gender

 Male

89

53 (59.6)

36 (40.4)

0.862

 Female

38

22 (57.9)

16 (42.1)

Tumor size (cm)

 <5

77

40 (51.9)

37 (48.1)

0.043

 ≥5

50

35 (70.0)

15 (30.0)

Differentiation

 Well or moderately poor

36

20 (55.6)

16 (44.4)

0.614

91

55 (60.4)

36 (39.6)

TNM stage

 I-II

29

12 (41.4)

17 (58.6)

0.028

 III-IV

98

63 (64.3)

35 (35.7)

Depth of invasion

 T1-T3

11

6 (54.5)

5 (45.5)

0.750

 T4

116

69 (59.1)

47 (40.5)

Tumor location

 Proximal

44

30 (68.2)

14 (31.8)

0.128

 Distal

83

45 (54.2)

38 (45.8)

Lauren classification

 Intestinal type

74

47 (63.5)

27 (36.5)

0.227

 Diffuse type

43

28 (52.8)

25 (47.2)

Lymph node metastasis

 N0-1

40

18 (45.0)

22 (55.0)

0.029

 N2-3

87

57 (65.5)

30 (34.5)

  1. P values determined using the χ2 test.